Eurofins Genomics Opens State-of-the-Art Facility in Louisville, KY
Tuesday, March 1, 2016
Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, announces the opening of its new state-of-the-art manufacturing and services facility in Louisville, KY, in the US. The large, 65,800 ft2 (6,113 m2) facility functions as the Group's central genomics laboratory in North America, focusing on the custom production of DNA and RNA oligonucleotides synthetic gene synthesis, and genomics services including DNA sequencing,
synthetic biology, and next generation sequencing (NGS).
As a leader in analytical laboratory technology, Eurofins continues to expand its global infrastructure of advanced laboratories. Since 2005, Eurofins has invested over $800,000,000 dollars to add or modernize over 350,000m2 of laboratory surface to its network, and plans to add another 120,000m2 by the end of 2017. The Louisville, KY facility will be one of the newest and
most advanced genomics facilities in the world. As a multi-functional hub, the site will also house other activities such as food and microbiology testing, which should foster diversity and synergy between scientific applications of molecular testing.
The company will introduce new, proprietary synthesis technology in the new facility, which will lead to increased quality and reliability in its oligonucleotides production capabilities. Quality standards implemented during construction are already among the highest in the industry and supported by several internationally recognized certifications such as ISO 9001:2008, ISO 13485: 2003 and an FDA certification for GMP production.
Located in the central hub for a major courier service operator, the new site offers unparalleled accessibility to the major cities in the US, and will allow Eurofins Genomics to become the fastest provider of genomics services in the marketplace. This should, in turn, allow for faster, more seamless service delivery to scientists nationwide. Furthermore, Louisville's highly trained workforce aligns well with the advanced production processes that Eurofins Genomics and other biotech firms require.
Comment from Dr. Gilles Martin, Eurofins Scientific CEO: "We are proud to open our newest genomics competence center in Louisville, KY. Our ambition is to make it the most modern and innovative facility of its kind in the world. This state-of-the-art laboratory reflects the Group's commitment to quality, innovation, and to contributing to the advancement of scientific research and health sciences around the globe."
Comment from Matt Bevin, Governor of Kentucky: "We are pleased to welcome Eurofins Scientific to Kentucky and excited about the opportunity to create jobs in the promising career field of genomics right here in Louisville. We are glad they will be taking advantage of the many logistical capabilities that cannot easily be replicated by other states. It is a testament to the quality of Louisville's workforce and further indication that Kentucky is open for business."
Comment from Greg Fisher, Mayor of Louisville: "Eurofins is a great example of the type of global leader our city wants to attract. A modern, innovative company that delivers, bringing together two of our five main economic development clusters - logistics, and lifelong wellness and aging care. Our city's central location, with world-class logistics, will help Eurofins get their products in, tested and returned more efficiently than anywhere else. This is a big win for Louisville as we continue to attract and support leaders in these industries."
For more information about Eurofins, please visit www.eurofins.com or contact:
|Eurofins MWG Operon LLC
North America: (+1) 1-800-688-2248Europe: (+49) 8092 8289-77
Asia: (+81) 03-5492-7001
| Investor Relations
Eurofins Scientific GroupPhone: + 32 2 766 1620
Notes for the editor:
About Eurofins Genomics
Eurofins Genomics is an international leader for genomic products and services, including DNA and RNA synthesis, DNA and next generation sequencing, synthetic gene synthesis, and applied genomics. The company's strengths are its commitment to the latest technology and lab processes, strong customer orientation, fast service, and high quality standards.
As a member of the Eurofins group, the genomics division contains major offices and production facilities in the United States, Europe, and Asia. Eurofins Genomics' customers encompass a wide variety of industries including life science, pharma, diagnostics, food, agriculture, biotechnological and research markets around the world. Visit www.eurofinsgenomics.com for more information.
Eurofins - a global leader in bio-analysis
Eurofins Scientific is the world leader in food, environment and pharmaceutical products testing. It is also one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.
With over 22,000 staff in more than 225 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.